Complete response to sorafenib in a patient with recurrent hepatocellular carcinoma |
| |
Authors: | Hong-Bo Huan Wan-Yee Lau Feng Xia Kuan-Sheng Ma Ping Bie |
| |
Affiliation: | Hong-Bo Huan, Wan-Yee Lau, Feng Xia, Kuan-Sheng Ma, Ping Bie, Institute of Hepatobiliary Surgery, Southwest Hospital, Southwest Cancer Center, Third Military Medical University, Chongqing 400038, ChinaWan-Yee Lau, Faculty of Medicine, The Chinese University of Hong Kong, Shatin, Hong Kong |
| |
Abstract: | Partial hepatectomy is still the treatment of choice aiming at a cure for patients with hepatocellular carcinoma (HCC), provided that the patient can tolerate the treatment. For patients with multiple recurrent HCC after partial hepatectomy which cannot be treated by re-hepatectomy or local ablative therapy, the prognosis is extremely poor. Sorafenib is a molecular-targeted agent which has been demonstrated in two global phase III randomized controlled trials to show survival benefit for advanced HCC. Here, we present a 56-year-old patient with HCC who showed complete clinical response after sorafenib was used for tumor recurrence which developed 3 mo after partial hepatectomy. There was no evidence of progression of disease for 60 mo till now after continuous treatment with sorafenib. |
| |
Keywords: | Hepatocellular carcinoma Partial hepatectomy Sorafenib Complete response |
|
| 点击此处可从《World journal of gastroenterology : WJG》浏览原始摘要信息 |
|